Curewize successfully completed the clinical trial of its lead product ProALL on a cohort of acute lymphoblastic leukemia (ALL) patients from a European National Registry Study. The company has also successfully completed trial for prostate cancer patients, accurately detecting patients who can be managed by active surveillance.

1. 07/05/2018 Curewize Successfully Completed Clinical Trial on Lab Test Revealing Acute Lymphoblastic Leukemia Patients' Optimal Treatment …
https://finance.yahoo.com/news/curewize-successfully-completed-clinical-trial-130000242.html 1/2
Company's Solution is a MicroRNA Biomarker Detecting Patient's
Risk for Relapse at Diagnosis
YOKNEAM, Israel, April 3, 2018 /PRNewswire/ --
Curewize Health Ltd. is a leader in the field of personalized medicine
capable of providing diagnostic solutions to address major unmet
market needs, across several types of cancer. Curewize successfully
completed the clinical trial of its lead product ProALL on a cohort of
acute lymphoblastic leukemia (ALL) patients from a European National
Registry Study. ProALL is being produced for deciding on ALL
patients risk-based treatment group, varying from standard to intense.
Curewize solution reveals patients' prognosis by use of one bone
marrow sample taken at diagnosis; compared to the current gold
standard lab tests, which require 1 to 3 months for results and between
2 to 4 bone marrow aspirations. ProALL adds unique insight on ALL
patients relapse risk, also identifying very high risk patients who
succumb to cancer relapse, even with the intense treatment regimen.
Newly approved cancer drugs may be the most optimal treatment
choice for these refractory patients.
Curewize CTO, Dr. Nir Dotan: "Now that the clinical standardization of
ProALL is completed, we will produce the lab test and offer for trial
utility to the National Oncology groups. ProALL can reach many patients
at an expedited pace through acceptance of the lab test by the national
organizations."
Curewize CEO, Dr. Jennifer Yarden: "The successful clinical trial of
our lead product paves the way for our product portfolio. Our plan is to
create a large menu of lab tests by industrializing biological markers
with good proof of concept using our platform technology."
About Curewize: Curewize product portfolio is based on its platform
technology for quantifying microRNA, the master regulators of gene
activity. Curewize pipeline includes a blood test, ProALL , for long-
BM
BM
BM
BM
BL
Curewize Successfully Completed
Clinical Trial on Lab Test Revealing
Acute Lymphoblastic Leukemia
Patients' Optimal Treatment Regimen
PR Newswire April 3, 2018

2. 07/05/2018 Curewize Successfully Completed Clinical Trial on Lab Test Revealing Acute Lymphoblastic Leukemia Patients' Optimal Treatment …
https://finance.yahoo.com/news/curewize-successfully-completed-clinical-trial-130000242.html 2/2
term and frequent monitoring of ALL patients, and a companion
diagnostic lab test for deciding on the treatment of solid cancers with
NAMPT and PARP inhibitors. Our biomarker directly controls NAMPT
activity, a producer of cell energy, consumed by PARP for correcting
DNA breaks in rapidly growing cancer cells. Curewize is a private
company, owned by the co-founders Youdim Pharmaceutical Ltd.,
Dr. Jennifer Yarden and Mr. Ossie Weitzman. Curewize started its
activity through the incubator program in June 2015 and due to its
successful results is now continuing with an additional year under the
Israeli Innovation Authority grant program.
Contact:
Dr. Jennifer Yarden
jenyarden@curewize.com
+972-4-9090016